Now is the time for the committee to review PURPA and its associated impacts.
Greg Walden
The Public Record
Greg Walden is a former U.S. Representative from Oregon, serving in the House from 1999 to 2021. A member of the Republican Party, he represented Oregon's 2nd congressional district. During his tenure, Walden was known for his work on issues related to healthcare, telecommunications, and energy policy. He played a significant role in the passage of the 21st Century Cures Act, which aimed to accelerate medical product development and bring new innovations to patients more quickly.
In passing PURPA, Congress took the first step towards competition within the electricity sector by allowing electricity generation to be independent of regulated monopolies for the first time.
As a committee with jurisdiction over both Medicare and Medicaid, we have a special obligation to thoughtfully examine this unique opportunity.
Well, good morning, Mr. Chairman and members of the committee and our distinguished panelists.
It's time for Congress to legislate the rules of the internet, and stop the ping-pong game of regulations and litigation.
I believe now, as I did then, that we should work together to write bipartisan legislation to protect the internet from bad actors who want to use their unfair advantage to block, throttle, or, in other ways, engage in bad behavior.
We want to improve the integrity of them. We want to look at the vulnerabilities and the current laboratory fee schedule.
I have cosponsored this legislation in the past, and I will continue to support it.
No crook should ever be less afraid of defrauding the Medicare program or taking advantage of a beneficiary simply because the penalties haven't been updated in decades.
With this program growth, concerns have surfaced about HRSA's ability to adequately oversee the program.
American consumers have come to expect safe, reliable, and affordable supplies of power--regardless of how they receive their electricity.
The committee is already ramped up its top to bottom oversight of many aspects of the cost drivers in our health care system and we have more work to do.
Since its creation by Congress in 1992, the 340B drug pricing program has provided lifesaving medicines at reduced prices to certain safety net health care providers.
I look forward to learning more about the state of the vital industry and hearing your thoughts regarding what, if any, reforms could help to achieve greater efficiencies, reliability, and competition in the wholesale markets while also…
Thank you, Mr. Chairman, for this hearing. This committee has really been ramping up its top-to-bottom oversight of many aspects of our health care system.
I want to commend my colleague from Oregon for his good work on this part of the bill. Mr. Speaker, I yield 1 minute to the gentleman from Oklahoma (Mr. Mullin).
I thank my colleague from New Jersey for his good work and kind comments on our legislation that we put together. Mr. Speaker, I yield 1 minute to the gentleman from Texas (Mr. Barton), the former chairman of the full committee. (Mr…
Addiction is an equal opportunity destroyer. It is a crisis that does not pick people based on their age, race, or socioeconomic status.
I believe Morgan Griffith's bill, H.R. 1703, is a serious, well-thought-out policy proposal.
In Oregon, more people now die from drug-related overdoses than from automobile accidents--and sadly, that is not unique to my home state.
Despite a report released by the Centers for Disease Control last week which indicates that the number of opioid prescriptions has decreased over the past five years, the rates are still three times as high as they were in 1999.
We need to be able to have more timely and reliable data so we can better understand and address the full scope of the problem.
It is past time for Congress to act, and as FDA's authorizing committee it is our job to clarify the statute.





